Idiopathic pulmonary fibrosis: Combating on a new turf

The Lancet Respiratory Medicine

Volumn 4, Issue 6, 2016, Pages 430-432

  Raghu, Ganesh ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; NINTEDANIB; PIRFENIDONE; PREDNISONE;

ALLERGIC PNEUMONITIS; ANAMNESIS; CHRONIC HYPERSENSITIVITY PNEUMONITIS; CLINICAL EVALUATION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; INTERSTITIAL PNEUMONIA; MICROBIOME; NOTE; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FUNCTION; SURVIVAL; SYMPTOM; DISEASE MANAGEMENT; ENVIRONMENTAL EXPOSURE; FEMALE; LUNG FUNCTION TEST; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; DISEASE PROGRESSION; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84969988899     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30106-0     Document Type: Note

References (16)

1. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664. American Thoracic Society.
2. Raghu G, Collard HR, Egan J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
3. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014, 1:566-572.
4. Morell F, Villar A, Montero MA, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013, 2:685-694.
5. Raghu G, Anstrom K, King TE, et al. Idiopathic pulmonary fibrosis clinical research network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1068-1977.
6. King T, Bradford W, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092.
7. Richeldi L, Du Bois R, Raghu G, et al. Efficacy and safety of nintedanib in Idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
8. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2093-2101. The Idiopathic Pulmonary Fibrosis Clinical Research Network.
9. Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med 2015, 3:473-482.
10. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015, 192:e3-e19.
11. Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis; an analysis of data from three randomized controlled trials. Lancet Respir Med 2013, 1:369-376. for the IPFnet investigators.
12. Raghu G Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet 2012, 380:699-701.
13. Ahluwalia N, Shea B, Tager M New therapeutic targets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014, 190:867-878.
14. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012, 185:1044-1048.
15. Fingerlin T, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013, 45:613-620.
16. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013, 1:309-317.